OncoSil Medical is entering a new and exciting phase as we work towards commercialising the OncoSil™ device, and ultimately achieving our goal of transforming the prognosis for patients with pancreatic cancer.
Daniel Kenny, CEO, MD
Chief Executive Officer
and Managing Director
Daniel Kenny joined OncoSil Medical in January 2015 with almost 30 years’ experience in the Global Pharmaceutical and Medical Device industry. Daniel is an accomplished and proven biopharmaceutical business leader and in his career he has developed and successfully driven business with industry leaders such as Roche, Allergan and Baxter working in Australia, EMEA and the US.
Prior to joining OncoSil Medical, Daniel held the position of Chief Commercial Officer at ABIVAX a Paris based global biopharmaceutical company specialising in the development of novel vaccines and anti-virals.
At Baxter Daniel served as Global Franchise Head Vaccines overseeing all Franchise Operations. Before this role, Daniel served as Vice President Baxter BioScience, EMEA with responsibility for all marketing and key business programmes in support of regional sales exceeding $1.9bio.
Daniel also served with Roche as Global LifeCycle Leader for Roaccutance, a product generating sales in excess of CHF 1.1 bio (2002) assuming responsibility for all global strategic marketing and business development activities. Prior to this role he was International Medical Manager and Medical Science and Safety Team leader responsible for post NDA clinical development strategy and critical issue work ups for regulatory authorities.
Daniel completed over 10 years in clinical research in the fields of Ophthalmology with the Royal Australian College of Ophthalmologists and the University of Sydney and HIV/AIDS research at the University of New South Wales, Sydney, Australia prior to joining the pharmaceutical industry.
Daniel is a graduate in Physics from the University of New South Wales and has completed Executive business studies at both INSEAD and London Business School. He is a graduate of the Australian Institute of Physics and is a member of the Australian Institute of Company Directors.
Chief Financial Officer
Karl Pechmann is a Chartered Accountant and Chartered Secretary with over 15 years of experience in his field. Prior to joining OncoSil, Karl held the position of CFO and Company Secretary of a regulatory technology company, Kyckr Limited (ASX: KYK).
His previous roles include Finance Director with ASX listed biotech company, Immutep Limited (ASX: IMM) and has held senior finance roles at both ASX-listed and multi-national organisations.
Global Head of
Manufacturing and Operations
David James is a highly experienced pharmaceutical manufacturing operations executive with more than 25 years’ experience in this field, including six years with leading cancer treatment company Sirtex Medical (ASX: SRX) as Global Operations Manager.
During his time at Sirtex, David was responsible for managing the global operations team including production, logistics, customer service, and engineering. This included responsibility for the design, construction, and commissioning of Sirtex’s first in-house manufacturing plant in Wilmington DC, in the US.
David has a Masters in Business and Technology from the University of New South Wales, and a Bachelor of Science from the University of Newcastle. David is a Chartered Chemist with the Royal Australian Chemical Institute and managed his own consultancy business before joining Oncosil.
Sales and Marketing Director
Michael Warrener has over 15 consecutive years experience in the implantable radioactive microspheres space in treatment of liver cancer, joining Sirtex Medical in 2002 and most recently in the treatment of pancreas cancer with Oncosil Medical.
His responsibilities have been focused on the commercialisation of these innovative therapies and include 5 years with Sirtology focused on product design development, quality management, regulatory and design dossier submissions for CE Marking in the European Union.
Michael moved from Sirtex Sydney to Bonn, Germany in 2003 as the European Director Sales and Marketing to establish the EU market as well as Scandanavian countries and a number of middle eastern countries.
VP Regulatory Affairs
Nicole Wilson is a former Sirtex Medical Global Regulatory Affairs Manager with 10 years Regulatory Medical Device experience. She is a Regulatory Affairs specialist focused on quality compliance and marketing registrations in the Asia, South America and middle East.
Principal for the regulatory approvals in Brazil, Argentina and UAE for Sirtex.
President of US Operations
Charles Rowland has had a successful career building and commercialising early stage medical device companies, predominantly in the interventional oncology and cardiology industries.
Prior to joining OncoSil Medical, Charles has launched the US subsidiary for Sirtex Medical and built a highly successful sales, marketing and operations team. In his role he developed strong relationships with many leading US cancer hospitals and with key physicians in the field. During his four years with Sirtex, the US operations grew from zero to over $15 million accounting for almost 80% of the company’s global revenues. He has served on the Sirtex Board of Directors.
Charles has held senior leadership positions at other early stage medical device companies. He co-founded and raised private funding for Ralin Medical/LifeWatch, a cardiac device and patient monitoring company which grew to around $20 million in revenues and was purchased by CardGuard.
President of EMEA
Nigel Lange has over 30 years of experience in the medical devices and pharmaceutical industries and has a track record of success in regional and global leadership roles.
He brings with him a wealth of management experience across sales and marketing, commercialisation, general management, M&A and corporate turnaround. Since 2017, Nigel served as Group Commercial Officer of SirTex Medical where he was responsible for all commercial aspects of the global business. In addition, in the early part of 2017, Nigel served as Interim Group CEO assuming 100% responsibility for the management of all business units and operations globally with full P&L responsibility. In his role as Interim Group CEO Nigel engineered a restructure of the business which resulted in the realisation of a A$45m cost saving.
From 2015 to 2017, Nigel held the role of Interim Chief executive Officer (Asia Pacific) where he was responsible for all regional business units, operations and regulatory affairs. In these roles, he was heavily involved in strategic licensing agreements with third parties and participated in mergers and acquisitions and other corporate activity.
From 2003 to 2016, Nigel served as Chief Executive Officer of SirTex’s European business where he was responsible for establishing the European division of SirTex. In this role, he led the commercialisation of SIR-Spheres into the European market and established its Selective Internal Radiation Therapy (SIRT) as the standard of care for liver cancer treatment in over 300 centres across Europe and the Middle East as well as achieving market penetration in all major EU markets.
Central to many of these roles has been Nigel’s focus in delivering strong outcomes for all key stakeholders, through a clear focus on strategy, people and end users.
Nigel holds a Bachelor of Commerce from the University of Windsor, Ontario and a Bachelor of Arts from York University, Ontario.
Between them, the four OncoSil Medical board members have extensive knowledge of biotechnology and medical innovation, coupled with many years of experience in the pharmaceutical and medical science fields.
Dr Chris Roberts AO
BE(Hons), MBA, PhD, Hon DSc(Macq), Hon DSc(UNSW), FTSE, FAICD, Hon FIEAust
Dr Roberts is a highly experienced director and senior executive with 40 years’ experience in the medical innovation space. He was CEO of Cochlear Limited (ASX: COH) from February 2004 to August 2015.
Dr Roberts was also previously Chairman of Sirtex Medical Ltd (ASX: SRX), from March 2000 to December 2002, and was Executive Vice-President of global sleep disorder treatment company ResMed Inc (NYSE: RMD, ASX: RMD) from 1992 to 2004. Dr Roberts is a PLuS Alliance Professor appointed across 3 universities: UNSW, King’s College London and Arizona State University. Dr Roberts also sits on the boards of a number of other entities and groups including; Innovation Science Australia, Biomedical Translation Fund, Jobs for NSW, and the NHMRC’s Health Innovation Advisory Committee.
Dr Roger Aston
Dr. Roger Aston, BSc (Hons) PhD serves as a Non-Executive Director of OncoSil Medical. He has had extensive experience on boards of many biotechnology and pharmaceutical companies, and has been CEO of Pitney Pharmaceuticals Ltd, pSiMedica, pSiOncology PTE Ltd, Peptech Ltd and Cambridge Antibody Technology.
In 2001, Dr Aston co-founded pSivida Limited. He served as Chief Executive Officer of Mayne Pharma Group Limited until February 15, 2012. During his career, Dr Aston has been closely involved in start-up companies and major pharmaceutical companies. Dr Aston is currently a director and Chairman of Immuron Limited (ASX:IMC), Director and Chairman of Regeneus Limited (ASX:RGS) and Director and Chairman of ResApp Limited (ASX:RAP). Roger Aston’s principal activity is as Executive Chairman of Pharmaust Ltd (ASX:PAA).
Aspects of his experience include FDA and EU product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors.
Dr Aston is both a scientist and seasoned biotechnology entrepreneur, with a successful track record in both fields. He currently has several executive and non-executive board positions with prominent biotechnology companies.
Dr Martin Cross
B.SC (Hons) and Ph.D. (Aberdeen) FAICD
Dr Cross is a highly regarded pharmaceutical executive with over 30 years’ experience including corporate and industry leadership roles directly influencing healthcare policy and government legislation in Australia and global business management, marketing and sales roles.
From 2013 to 2015, Dr Cross was Chairman of Medicines Australia, the country’s peak body representing the research based pharmaceutical industry in Australia. Prior to leading Medicines Australia, from 2010 to 2013 Dr Cross was Chairman of both the Generics Medicine Industry Association and Pharmaceutical Industry Council. During this time, Dr Cross was also Managing Director of Alphapharm in Australia and New Zealand, with responsibility for 750 employees and sales of over US $500m per annum.
From 2003 to 2008, Dr Cross was Country Head and Managing Director of Novartis Australia and New Zealand, and Head of Global Marketing and Sales Capabilities from 2001 to 2003, based in Switzerland.
Mr Michael Bassett
B. Econ, AICD
Mr Bassett has over 25 years experience in capital markets and has held senior management roles at Australia’s leading fund management and investment banking firms.
His career focus involved analysing, advising and investing in small-cap ASX-listed companies with strong prospects for shareholder value creation. Mr Bassett previously worked as Portfolio Manager for the successful Regal Australian Small Companies Fund with a significant focus on Life Science companies. Prior to this he held senior management positions with Credit Suisse’s Institutional Equities business, Deutsche Asset Management and Merrill Lynch.
We are currently in the process of updating our website.
Please contact us using the email address below for any information.